[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 590
Citations 0
Comment & Response
July 14, 2015

Drug-Drug Interactions in Patients Co-infected With HCV and HIV

Author Affiliations
  • 1Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
  • 2Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Tokyo, Japan
JAMA. 2015;314(2):186. doi:10.1001/jama.2015.6618

To the Editor In a small pilot study, Dr Osinusi and colleagues1 reported the safety and high sustained virologic response rate for combined treatment using ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, with sofosbuvir, an HCV NS5B polymerase inhibitor, in previously untreated, noncirrhotic patients with HCV genotype 1 and human immunodeficiency virus (HIV) co-infection. This study analyzed the changes in HIV parameters, such as HIV RNA level or CD4 T-lymphocyte count, and in renal function, such as serum creatinine level or estimated glomerular filtration rate.

First Page Preview View Large
First page PDF preview
First page PDF preview
×